LEO 138559
DrugLEO 138559 is a compound in development at LEO Pharma A/S
NCT Number: NCT03514511
The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.
The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of LEO 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis.
Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen per subject).
Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of LEO 138559 (one dose regimen per subject).
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Investigational site, Leeds, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For healthy subjects and subjects with atopic dermatitis:
For subjects with atopic dermatitis only:
Exclusion criteria
For healthy subjects and subjects with atopic dermatitis:
For subjects with atopic dermatitis only:
LEO 138559 is a compound in development at LEO Pharma A/S
LEO 138559 placebo
Time frame: Day 1 to Day 120
Time frame: Day 1 to Day 120
Time frame: Day 1 to Day 120
LEO Pharma
Industry
Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06687512
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ahmedabad, Gujarat, India
View Trial DetailsNCT05613062
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT05633355
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT05899816
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Scottsdale, Arizona, United States
View Trial Details